



ARTICLE

A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants

Chadi G. Abdallah^{1,2,3,4}, Kyung-Heup Ahn^{1,2}, Lynnette A. Averill^{1,2}, Samaneh Nemati^{1,2}, Christopher L. Averill^{1,2}, Samar Fouda^{1,2}, Mohini Ranganathan^{1,2}, Peter T. Morgan², Deepak C. D'Souza^{1,2}, Daniel H. Mathalon⁵, John H. Krystal^{1,2} and Naomi R. Driesen^{1,2}

Over the past decade, various *N*-methyl-D-aspartate modulators have failed in clinical trials, underscoring the challenges of developing novel rapid-acting antidepressants based solely on the receptor or regional targets of ketamine. Thus, identifying the effect of ketamine on the brain circuitry and networks is becoming increasingly critical. In this longitudinal functional magnetic resonance imaging study of data from 265 participants, we used a validated predictive model approach that allows the full assessment of brain functional connectivity, without the need for seed selection or connectivity summaries. First, we identified a connectome fingerprint (CFP) in healthy participants (Cohort A, $n = 25$) during intravenous infusion of a subanesthetic dose of ketamine, compared to normal saline. We then demonstrated the robustness and reproducibility of the discovered ketamine CFP in two separate healthy samples (Cohort B, $n = 22$; Cohort C, $n = 18$). Finally, we investigated the ketamine CFP connectivity at 1-week post treatment in major depressive disorder patients randomized to 8 weeks of sertraline or placebo (Cohort D, $n = 200$). We found a significant, robust, and reproducible ketamine CFP, consistent with reduced connectivity within the primary cortices and within the executive network, but increased connectivity between the executive network and the rest of the brain. Compared to placebo, the ketamine CFP connectivity changes at 1 week predicted response to sertraline at 8 weeks. In each of Cohorts A–C, ketamine significantly increased connectivity in a previously identified antidepressant CFP. Investigating the brain connectivity networks, we successfully identified a robust and reproducible ketamine biomarker that is related to the mechanisms of antidepressants.

Neuropsychopharmacology (2021) 46:478–485; <https://doi.org/10.1038/s41386-020-00864-9>

INTRODUCTION

Major depressive disorder (MDD) remains among the most disabling illnesses, with increased risk of suicide and high treatment resistance. Moreover, most standard MDD treatments are slow acting, requiring weeks to months to achieve full therapeutic effects. The discovery of the rapid-acting antidepressant (RAAD) effects of ketamine has generated excitement and optimism in the field [1–3]. Over the past two decades, there has been a longstanding desire to identify novel antidepressants that preserve the RAAD effects of ketamine, without its side effects and abuse liability [4]. Molecular and cellular hypotheses related to the mechanism of ketamine efficacy suggest a number of novel directions to pursue in RAAD drug development [5]. However, broadening the perspective to include ketamine's impact on brain functional connectivity networks may enrich the effort to identify novel treatment mechanisms. In particular, a network view of ketamine's effects may help us to better understand the underlying mechanisms, supplementing current knowledge of ketamine's neurochemical properties and regional brain targets.

Profiling the connectivity of all the brain's networks, a process termed functional connectome fingerprinting has been successfully applied to predict behavior (e.g., [6]) and recently identified

a unique connectome fingerprint (CFP) that predates and predicts response to antidepressants [7]. In the current study, we employed this predictive model approach to identify robust and reproducible functional connectivity signatures of ketamine. This approach is a combination of the network-restricted strength (NRS) methods and the connectome-based predictive modeling [8, 9]. The connectome-based predictive model is a series of analytic steps that selects and summarizes features, builds and applies models, and finally assesses their predictive significance [9]. Importantly, this predictive model retains the ability to back-translate findings to the original feature space, a unique advantage that is often lacking in many machine learning approaches [6, 9]. In the NRS approach, we use whole-brain parcellation along with the Akiki–Abdallah (AA) hierarchical connectivity atlas [7, 10] to significantly reduce the number of edges, while retaining the upstream canonical intrinsic network affiliations to the central executive (CE), default mode (DM), ventral salience (VS), dorsal salience (DS), subcortical (SC), sensorimotor (SM), and visual (VI) networks [11]. The main goal of this network-restricted strength predictive model (NRS-PM) is not to assess the strength of predictions, but rather to identify functional connectivity signature that is associated, significantly

¹Clinical Neuroscience Division, VA National Center for PTSD, West Haven, CT, USA; ²Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; ³Michael E. DeBakey VA Medical Center, Houston, TX, USA; ⁴Menninger Department of Psychiatry, Baylor College of Medicine, Houston, TX, USA and ⁵San Francisco VA Medical Center, University of California, San Francisco, CA, USA

Correspondence: Chadi G. Abdallah (chadi.abdallah@bcm.edu)

Received: 11 May 2020 Revised: 15 August 2020 Accepted: 10 September 2020

Published online: 23 September 2020

and consistently, with the outcome of interest (e.g., ketamine effects) [11]. This approach has many strengths, including: (1) the predictive model design may enhance reproducibility by providing protection against overfitting, which is an issue with traditional interpretive analyses; (2) the multivariate pattern analysis allows the full assessment of the connectome, without the inherent increase of Type I error due to univariate multiple comparisons or the need to limit the analysis to a few seeds; and (3) the results are, by design, network based that both informs the neurobiological models and facilitates the integration of findings.

In biomarker development, it is essential that the putative marker is: (1) robust, having a large effect size so it is evident even in relatively small samples; (2) reproducible, being stable within a population and generalizing to new observations; and (3) relevant, associated with the clinical outcome of interest such as predicting group differences or changes in clinical status or being responsible for these changes [12]. In this study, our primary aim was to evaluate the robustness and reproducibility of the effects of ketamine on human cortical functional connectivity (here termed, "ketamine CFP") across three samples of healthy participants (Cohorts A–C; $n = 18$ – 25). We previously found that the connectivity of a CFP identified during sertraline treatment predicted response to ketamine compared to active control in depressed patients [11]. Hence, as a secondary aim, we here investigated whether the connectivity of the ketamine CFP will predict sertraline antidepressant response in a randomized trial of patients with MDD (Cohort D; $n = 200$).

We hypothesized that the NRS-PM in Cohort A would identify a significant CFP of the effects of ketamine, and that this CFP would be robust and reproducible in Cohorts B and C. We also investigated, in Cohort D, whether the ketamine CFP connectivity predicts the antidepressant response in MDD patients treated with sertraline, compared to placebo. Finally, to assess the brain localization of ketamine's signature, we analyzed changes in connectivity strength of all nodes, termed the nodal fingerprint (NFP) [11].

METHODS

Participants and procedures

The data ($n = 265$) used in this study were collected as part of four independent trials [13–16]. Functional connectivity analyses were not performed previously in data collected in the primary sample (Cohort A). Therefore, the ketamine connectivity signatures were identified in Cohort A [14], while Cohorts B–D were used to assess robustness, reproducibility, and clinical relevance [13, 15, 16]. All studies were approved by Institutional Review Boards, and all participants signed informed consents.

Full details of the Trials A–D were reported previously [13–16] and are summarized in the Supplementary information. Of relevance to the current report, Cohort A ($n = 25$; mean age \pm SEM = 30 ± 1.9 years; 19 men), Cohort B ($n = 22$; mean age \pm SEM = 29 ± 1.5 years; 14 men), and Cohort C ($n = 18$; mean age \pm SEM = 28 ± 0.9 years; 18 men) included healthy subjects who received brain functional magnetic resonance imaging (fMRI), during administration of intravenous normal saline then ketamine as an intravenous bolus (0.23 mg/kg) followed by an intravenous infusion of 0.58 mg/kg throughout the scan. Participants were excluded if they had an unstable medical illness, a psychiatric disorder, or an MR contraindication. Cohort D ($n = 200$; mean age \pm SEM = 38 ± 0.9 years; 67 men) included unmedicated nonpsychotic patients with MDD who were randomized to a 8-week course of up to 200 mg daily sertraline or to placebo (Table S1). Participants received fMRI scans at baseline and at Week 1 of treatment [11, 16]. Depression severity was rated on the 17-item Hamilton Depression Rating Scale at baseline and at Week 8 after treatment.

Neuroimaging acquisition and processing

In the ketamine studies, fMRI scans were acquired during intravenous infusions of normal saline and then during ketamine, while subjects performed eight spatial working memory runs (voxel size = $3.1 \times 3.1 \times 5$ mm³; TR = 1500 ms, 166 frames; Cohort A/B) or three visual oddball runs (voxel size = $3.4 \times 3.4 \times 4.5$ mm³; TR = 2000 ms, 210 frames; Cohort C) [13–15]. In consideration of reports of time effects [17], functional connectivity measures were computed on the early runs (i.e., ~12 min) during each intravenous infusion of ketamine and of normal saline. In the MDD study, fMRI scans were acquired at rest ($3.2 \times 3.2 \times 3.1$ mm³; TR = 2000 ms; ~12 min; baseline and Week 1 sessions) [7, 11, 18]. All studies included high-resolution structural MRI. Brain scans from all studies underwent the same surface-based preprocessing, using a pipeline adapted from the Human Connectome Project (<https://github.com/Washington-University/HCPpipelines>) [19], as reported elsewhere [7, 11, 20–22]. Briefly, the preprocessing pipeline included FreeSurfer parcellation of structural scans, slice timing correction, motion correction, intensity normalization, brain masking, and registration of fMRI images to structural MRI and standard template. Then, the cortical gray matter ribbon voxels and each subcortical parcel were projected to a standard Connectivity Informatics Technology Initiative (CIFTI) 2 mm grayordinate space (i.e., gray matter area in CIFTI). ICA-FIX was run to identify and remove artifacts [23, 24], followed by mean grayordinate time series regression (MGTR) [25].

Connectome and nodal predictive models

Full details of the NRS methods were previously reported [8, 11]. Briefly, the A424 atlas is used to segment the whole-brain gray matter into 424 nodes, and to compute average time series within each node [11, 26–28]. The AA hierarchical connectivity at 50 modules (AA-50; Fig. S1), 24 modules (AA-24; Fig. S2), and 7 modules (AA-7) was used to determine the network affiliation of the A424 nodes (<https://github.com/emergelab>). The full connectome is the Fisher-z transformation of the pairwise correlation coefficients. NRS connectome is the pairwise average connectivity of all modules at AA-50 and AA-24 [11]. Nodal strength (nS) is the average connectivity of a node to all other nodes. Nodal internal NRS (niNRS) is the average connectivity between each node and all other nodes within the same canonical connectivity network (i.e., AA-7). Nodal external NRS (neNRS) is the average connectivity between each node and all other nodes outside its canonical connectivity network [11]. The predictive models used were adapted from the connectome-based predictive model approach [9], as previously detailed [11]. The modeling includes feature selection in training subsamples, followed by fitting a linear predictive model, then applying the model to the test subsample [9]. As previously established, we used 1000 iterations of tenfold cross-validation (CV) to ensure the stability of the models and to determine the statistical significance; that is by comparing true and random predictions [11].

Statistical analyses

Descriptive statistics were calculated prior to statistical analysis. Data distributions were checked using normal probability plots. The statistical significance threshold was set at 0.05 (two-tailed tests). MATLAB (version R2018a; Mathworks Inc.) and the Statistical Package for the Social Sciences (version 24; IBM) software were used for the analyses. False discovery rate (FDR; $q < 0.05$) was used to correct for multiple comparisons. FDR was applied on all secondary outcomes within a research question. Applying FDR across research questions did not affect the results. The improvement-by-treatment interaction was computed as the percent improvement in depression score multiplied by the treatment contrast (i.e., 1 for study drug and -1 for placebo control) [11]. NRS-PM at AA-50 is considered the primary CFP analysis, with two secondary CFPs at AA-24 and full connectome. The goal of the secondary CFPs is to inspect the upstream

modules (i.e., AA-24) and to test the model without applying the AA network restrictions (i.e., A424—the full connectome) [11]. Similarly, nS predictive model is considered the primary NFP analysis, with niNRS and neNRS as secondary analyses to interrogate the shifts within and between networks, which are not captured by nS [11]. Connectivity per fingerprint was computed by multiplying the connectivity features (e.g., NRS at AA-50) by the corresponding weighted fingerprint masks (e.g., the antidepressant CFP from [11]). Thus, the CFP connectivity is the sum of weighted estimates per subject per CFP. To facilitate the comparison across samples, the CFP connectivity values were standardized (*z* scored) within each cohort. Paired *t*-tests were used to examine the effects of ketamine on the connectivity of fingerprints. Pearson correlations were used to examine the association among connectivity of fingerprints and between ketamine fingerprints and depression improvement following sertraline, compared to placebo. The similarity between ketamine and depression CFP was quantified by computing the direct correlations between their weighted edges. The study atlases, codes, and predictive models will be made publicly available at <https://github.com/emergelab>.

RESULTS

Ketamine connectome fingerprint (CFP)

The primary analysis, at AA-50, identified a CFP that is significantly associated with ketamine infusion, compared to normal saline ($r =$

0.66, $CV = 10$, iterations = 1000, $p < 0.001$). Secondary analyses also identified significant CFPs at AA-24 ($r = 0.60$, $CV = 10$, iterations = 1000, $p < 0.001$, $q < 0.05$) and at the full connectome ($r = 0.65$, $CV = 10$, iterations = 1000, $p < 0.001$, $q < 0.05$). As shown in Fig. 1, ketamine infusion was associated with reduced connectivity within the primary cortices (SM and VI) and within the CE-SC modules, but increased connectivity between the CE-SC and the rest of the brain. For the DM and VS modules, there is a shift from connectivity with primary cortices during saline (i.e., negative predictive edges) toward increased connectivity with the CE-SC modules during ketamine infusion (i.e., positive predictive edges) (Fig. 1).

Due to the large number of predictive edges, visualizing the full connectome often yields indiscernible CFP [11]. However, inspecting the nodes with highest degree (i.e., top 2.5% of each of positive and negative predictive edges) revealed a pattern of connectivity signature comparable to the AA-50 CFP (Fig. 1c). The sum of edges of the full connectome model depicts the nodal degree of connectivity changes during ketamine, compared to normal saline. Note that only edges that were statistically significant in the model were depicted in the figures and included in the sum of edges.

Ketamine nodal fingerprint (NFP)

The primary analysis, based on nS, identified an NFP that is significantly associated with ketamine infusion, compared to normal saline ($r = 0.60$, $CV = 10$, iterations = 1000, $p < 0.001$). Secondary analyses also identified significant NFPs based on




Fig. 1 Ketamine connectome fingerprint (CFP). a–d Predictive models applied in healthy subjects receiving a subanesthetic dose of ketamine identified a unique CFP consistent with reduced connectivity in edges within the central-executive–subcortical regions and within primary cortices (i.e., negative predictive edges), along with increased connectivity between the central-executive–subcortical regions and the rest of the brain (i.e., positive predictive edges). The circular graphs are labeled based on the Akiki–Abdallah (AA) whole-brain architecture at 50 modules (AA-50; primary CFP), 24 modules (AA-24), and the full connectome with 424 nodes (A424). Modules and nodes are colored according to their affiliation to the seven canonical connectivity networks: central executive (CE), default mode (DM), ventral salience (VS), dorsal salience (DS), subcortical (SC), sensorimotor (SM), and visual (VI). Edges are colored based on the initiating module using a counter-clockwise path starting at 12 o'clock. Internal edges (i.e., within module) are depicted as outer circles around the corresponding module. Thickness of edges reflects their corresponding weight in the predictive model. The module abbreviations of AA-24 and AA-50, along with further details about the affiliation of each node are available at https://github.com/emergelab/hierarchical-brain-networks/blob/master/brainmaps/AA-AAc_main_maps.csv. Only edges of significant predictive models following correction are shown (all $p \leq 0.001$). For the full connectome, it is not possible to visually discern the underlying signature considering the large number of edges retained. Therefore, as in previous studies, the circular graph is thresholded using nodal strength within the full connectome fingerprint as cutoff to retain the highest top 2.5% negative predictive edges and top 2.5% positive predictive edges. Panel d shows the nodal degree of the full connectome fingerprint edges without a threshold. The color bar unit is arbitrary, reflecting the sum of weighted edges. All predictive models will be made publicly available at <https://github.com/emergelab>.




Fig. 2 Ketamine nodal fingerprint (NFP). **a** The nodal affiliation based on the Akiki-Abdallah (AA) hierarchical atlas at seven canonical intrinsic connectivity networks (i.e., AA-7): default mode (DM), central executive (CE), subcortical (SC), ventral salience (VS), dorsal salience (DS), sensorimotor (SM), and visual (VI). The AA-7 affiliation was used to compute nodal external network-restricted strength (neNRS) and nodal internal NRS (niNRS). Nodal predictive results using nodal strength (nS; primary NFP; **b**), neNRS (**c**), or niNRS (**d**) as input features in healthy subjects receiving a subanesthetic dose of ketamine. The nS findings (**b**) associated ketamine infusion with increased global connectivity in the central-executive-subcortical regions (red-yellow), but reduced connectivity in the primary cortices and the hippocampus (blue). The neNRS (**c**) and niNRS (**d**) findings demonstrate a connectivity shift during ketamine infusion with reduced internal within network connectivity and increased connectivity between the central-executive-subcortical modules and the remaining brain networks. Only nodes of significant predictive models following correction are shown (all $p \leq 0.001$). The color bar unit is arbitrary, reflecting the sum of weighted nodes. All predictive models will be made publicly available at <https://github.com/emergelab>.

niNRS ($r = 0.61$, $CV = 10$, iterations = 1000, $p < 0.001$, $q < 0.05$) and neNRS ($r = 0.65$, $CV = 10$, iterations = 1000, $p < 0.001$, $q < 0.05$). As shown in Fig. 2, ketamine infusion was associated with significant reduction in nS in the primary cortices and the hippocampus, but increased nS in the CE-SC regions. Inspection of the niNRS/neNRS results revealed a shift within the CE-SC networks, with reduced internal but increased external connectivity during ketamine infusion (Fig. 2c, d).

Generalizability of the ketamine fingerprints

We next investigated whether the above fingerprints identified in Cohort A, hereafter termed ketamine CFP/NFP, would generalize to new samples performing similar (Cohort B) or differing (Cohort C) tasks during infusion. Compared to normal saline, ketamine significantly increased the ketamine CFP connectivity at AA-50, AA-24, and full connectome in both Cohorts B and C (all $p \leq 0.001$, $q < 0.05$; Fig. 3a). Ketamine also increased ketamine NFP strength of niNRS and neNRS in both Cohorts B and C (all $p \leq 0.01$, $q < 0.05$; Fig. 3a). However, ketamine NFP of nS was significantly increased in Cohort C ($p = 0.001$, $q < 0.05$), but not Cohort B ($p = 0.17$; Fig. 3a).

Considering the excellent generalizability of the ketamine CFP, we further assessed the robustness and reproducibility of the NRS-PM in Cohorts B and C. As shown in Fig. S3, NRS-PM analyses identified significant CFPs in both Cohorts B and C, which were qualitatively and quantitatively comparable to the ketamine CFP established in Cohort A (see Supplementary information).

Relevance to antidepressants treatment

To assess the relevance of the ketamine signatures to the effect of antidepressants, we first investigated the association between the connectivity of these fingerprints and the percent improvement in depression scores following treatment with sertraline, compared to placebo in Cohort D. We found a significant positive correlation between percent improvement in depression scores at Week 8

and increased connectivity at Week 1 in each of the ketamine CFPs at AA-50 ($r = 0.30$, $df = 199$, $p < 0.001$, $q < 0.05$), AA-24 ($r = 0.27$, $df = 199$, $p < 0.001$, $q < 0.05$), and the full connectome ($r = 0.29$, $df = 199$, $p < 0.001$, $q < 0.05$), and the ketamine NFPs of nS ($r = 0.21$, $df = 199$, $p = 0.003$, $q < 0.05$), niNRS ($r = 0.21$, $df = 199$, $p = 0.003$, $q < 0.05$) and neNRS ($r = 0.26$, $df = 199$, $p < 0.001$, $q < 0.05$).

Next, we investigated the effects of ketamine on the antidepressant fingerprints previously identified by Nemati et al. [11] (Fig. S4). As shown in Fig. 3b, we found that in each of Cohorts A-C, ketamine significantly increased connectivity in the antidepressant CFPs and NFPs. Note that the data were not combined across cohorts in order to assess both the robustness (i.e., significance in small samples) and the reproducibility of the fingerprints across samples.

Finally, we investigated the association between the ketamine and antidepressant fingerprints. Investigating the total connectivity across healthy and depressed subjects, we found positive correlations between ketamine and antidepressant CFPs connectivity ($r = 0.95$, $df = 264$, $p < 0.001$, $q < 0.05$; Fig. 3c), as well as between ketamine and antidepressant NFPs connectivity ($r = 0.89$, $df = 264$, $p < 0.001$, $q < 0.05$; Fig. 3d). Moreover, independent of individual connectivity, the ketamine and antidepressant CFPs weighted edges were found to be significantly correlated ($r = 0.42$, $p = 1.0 \times 10^{-104}$).

DISCUSSION

The study successfully identified a robust and reproducible biomarker of ketamine's effect on brain networks (i.e., ketamine CFP). Secondary measures of CFPs were also significant (Figs. 1 and S5). Both primary (AA-50) and secondary (AA-24 and full connectome) CFPs were generalized to two separate samples (Cohorts B and C). While the study identified a significant ketamine NFP, this biosignature generalized to Cohort C, but not




Fig. 3 Reproducibility and clinical relevance of the ketamine connectome (CFPs) and nodal fingerprints (NFPs). **a** The ketamine functional connectivity fingerprints identified in Cohort A were examined in Cohorts B and C. Ketamine significantly increased all connectivity fingerprints during infusion, except the nodal strength (nS) NFP in Cohort B. These findings demonstrate the robustness and reproducibility of the ketamine CFP. **b** In three cohorts of healthy participants, ketamine significantly increased connectivity of previously established antidepressant fingerprints. These findings demonstrate the clinical relevance of the ketamine CFP and its generalizability to antidepressants with differing initial neurochemical targets. **c, d** Across healthy and depressed subjects, there are high associations between the total connectivity of ketamine and antidepressant fingerprints. AA Akiki–Abdallah hierarchical connectivity atlas, AA-50 CFP using AA at 50 modules, AA-24 CFP using AA at 24 modules, FC full connectome using 424 nodes (i.e., A424), neNRS NFP using nodal external network-restricted strength, niNRS NFP using nodal internal NRS. * is used for $p \leq 0.05$, ** for $p \leq 0.01$, *** for $p \leq 0.001$, **** for $p \leq 0.0001$, ***** for $p \leq 0.000001$. z is computed as the standardized sum of weighted estimates of connectivity per subject per fingerprint.

B, raising concerns about the reproducibility of the nS biomarker. Nonetheless, it is important to note that as an average of all connections, nS is network agnostic and is not able to capture the dynamic shift within and between networks. As shown in Fig. 1, the ketamine CFP is characterized by both reduction in internal and increase in external connectivity. For these network shifts, niNRS and neNRS are more suitable measures. As such, these secondary NFPs were highly robust and reproducible across all cohorts.

A major secondary finding is that the identified ketamine CFP appears to be directly relevant to the treatment of depression, as evident by the positive correlation between the increase of ketamine CFP connectivity and treatment response following antidepressant treatment compared to placebo in Cohort D. Moreover, ketamine was found to significantly increase antidepressant CFP connectivity in each of Cohorts A–C. Furthermore, there is high association between the ketamine and antidepressant CFPs in both healthy and depressed populations. These results are consistent with a previous report showing that, compared to an active control, the ketamine-induced changes in the antidepressant CFP connectivity during infusion predict treatment response at 24 h in MDD patients [11]. Importantly, the mechanisms of action of ketamine and monoaminergic antidepressants are believed to converge at the level of synaptic connectivity [4, 29]. Both modalities are thought to affect neurotrophic factors leading to changes in synaptic plasticity and ultimately brain circuitry and network reconfiguration, which subsequently results in antidepressive changes [30]. It remains to

be seen in future studies whether the connectivity of ketamine and antidepressant CFPs would also predict response to other treatment modalities, such as electroconvulsive therapy and transcranial magnetic stimulation.

Qualitatively, the ketamine CFP may indicate a pattern of increased top-down control, showing a shift from internal connectivity within SM–VI and within CE–SC modules toward external connectivity between executive regions and primary cortices. In the DM and VS modules, there is also a shift from interference with primary cortices toward increased connection with the CE–SC modules (Fig. 1). This dynamic internal to external connectivity shift is also demonstrated quantitatively with the distribution of niNRS and neNRS NFPs. As evident in Fig. 2, nodes within the CE network have shown both reduction in niNRS and increase in neNRS, which may have contributed to the dampened effects on nodal nS. The latter is a combination of internal and external connections (i.e., niNRS and neNRS).

The pattern of ketamine-induced enhanced executive connectivity is reminiscent of findings with the antidepressant CFP [11]. It is also consistent with a model that associates depression with disconnection between the executive regions and the rest of the brain, combined with increased interference from the DM and VS modules, showing higher connections to primary cortices. In this model, ketamine and other antidepressants will exert their therapeutic effects by reversing this pathology. Of relevance, numerous MDD studies have shown reduced nS (also known as functional connectivity strength or global brain connectivity) within the prefrontal cortex (PFC) [13, 31–36], which might reflect the

hypothesized executive disconnection in depression. Importantly, it was repeatedly shown that ketamine reverses this nS prefrontal dysconnectivity during infusion and at 24 h post treatment of depressed patients [13, 22, 31] (but not at 48 h [33]). Other studies have also associated executive and DM alterations with depression pathology and treatment [37–40].

The current results may relate to previous ketamine studies of functional connectivity [15, 41–45]. However, a limitation of the current method is that the modules are not directly comparable to previous seeds and networks. Furthermore, the ketamine CFP was derived from task data collected during ketamine infusion and may differ from that observed under rest. Task-related connectivity typically reflects task cognitive operations and often differs from resting connectivity [46]. It has been shown that seed-based connectivity in the executive control network under ketamine differs between task and resting state [15]. Task data may have been especially useful, in the current investigation, because the oddball and the spatial working memory task increase demands upon the PFC. Since depressed individuals have prominent prefrontal disruption [34], task data may highlight connectivity similarities between individuals on ketamine and depressed individuals. Furthermore, as previously validated, we used ICA-FIX + MGTR in the current study to reduce artifacts and to facilitate interpretation across studies (see Supplementary information). Therefore, the current findings should be interpreted and replicated within this context.

Despite these limitations, the ketamine CFP clearly shows that ketamine-induced connectivity changes combine increases and reductions in a network informed fashion. A leading model of the mechanisms of ketamine is that chronic stress pathology (CSP) and depression are associated with reduced synaptic connectivity (i.e., reduced synaptic density and strength) and that ketamine rapidly increases synaptic connectivity leading to robust and sustained antidepressant effects [47, 48]. In the PFC, and perhaps in the hippocampus, this CSP model has strong preclinical evidence and broad supportive human data [49]. However, what is often less highlighted in the literature is that CSP is also associated with increased synaptic connectivity in the nucleus accumbens and other brain regions [30, 50]. Conversely, ketamine effects are associated with reduced synaptic connectivity in the nucleus accumbens [50, 51]. Together, these data suggest that both increases and reductions in synaptic connectivity are required to successfully induce antidepressant effects. Considering that the ketamine-induced synaptic plasticity is activity dependent [52], we hypothesize that during ketamine infusion, a glutamate surge [53] within the CE synaptic connections gives rise to unique network shifts consistent with the functional connectivity changes captured by the ketamine CFP. This transient pattern of altered synaptic neurotransmission is ultimately translated into changes of synaptic density and strength, which leads to rapid and sustained normalization of functional networks and to RAADs effects. This network-dependent model may provide partial explanation for the failure of other *N*-methyl-*D*-aspartate modulators [54]. For example, rapastinel has shown significant increase in PFC synaptic connectivity but failed in clinical trials [55]. Similarly, it may provide insight into why local injection of rapamycin into the PFC [56], but not its systemic administration [57, 58], block the ketamine RAAD effects. In this network-dependent model, it is hypothesized that interventions that affect synaptic connectivity regionally, without inducing the full spectrum of ketamine CFP changes, are unlikely to induce robust antidepressant effects. Conversely, interventions that locally affect synaptic connectivity (e.g., rapamycin in PFC), which subsequently disrupt the ketamine CFP changes, may result in blockade of ketamine's RAAD effects. However, it is critical to underscore the speculative nature of this network-dependent model and the need for confirmatory causal evidence in future studies.

FUNDING AND DISCLOSURE

This work was supported by National Center for Advancing Translational Science Grant No. 1UH2TR000960-01, National Institute on Alcohol Abuse and Alcoholism Grant No. P50AA12870, Yale Center for Clinical Investigation Grant No. UL1 RR024139, NIMH (K23MH101498), GlaxoSmithKline, VA Career Development Award (IK2-CX0001873), American Foundation for Suicide Prevention (YIA-0-004-16), and the Department of Veterans Affairs through its support for the Veterans Affairs National Center for Posttraumatic Stress Disorder. The content of this report is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors, the Department of Veterans Affairs, NIH, or the US Government. CGA has served as a consultant, speaker, and/or on advisory boards for Genentech, Janssen, Psilocybin Labs, Lundbeck, Guidepoint and FSV7, and editor of *Chronic Stress* for Sage Publications, Inc.; he also filed a patent for using mTORC1 inhibitors to augment the effects of antidepressants (August 20, 2018). MR has in the past 3 years, or currently receives, research grant support administered through Yale University School of Medicine from INSYS Therapeutics. DCD receives research support administered through Yale University School of Medicine currently from Takeda, and in the past 3 years from INSYS Therapeutics. DHM is a consultant for Boehringer Ingelheim, Takeda, Alkermes, and Upsher-Smith. JHK is a consultant for AbbVie, Inc., Amgen, Astellas Pharma Global Development, Inc., AstraZeneca Pharmaceuticals, Biomedisyn Corporation, Bristol-Myers Squibb, Eli Lilly and Company, Euthymics Bioscience, Inc., Neurovance, Inc., FORUM Pharmaceuticals, Janssen Research & Development, Lundbeck Research USA, Novartis Pharma AG, Otsuka America Pharmaceutical, Inc., Sage Therapeutics, Inc., Sunovion Pharmaceuticals, Inc., and Takeda Industries; is on the Scientific Advisory Board for Lohocla Research Corporation, Mnemosyne Pharmaceuticals, Inc., Naurex, Inc., and Pfizer; is a stockholder in Biohaven Pharmaceuticals; holds stock options in Mnemosyne Pharmaceuticals, Inc.; holds patents for Dopamine and Norenergic Reuptake Inhibitors in Treatment of Schizophrenia, US Patent No. 5,447,948 (issued September 5, 1995), and Glutamate Modulating Agents in the Treatment of Mental Disorders, US Patent No. 8,778,979 (issued July 15, 2014); filed a patent for Intranasal Administration of Ketamine to Treat Depression—US Application No. 14/197,767 (filed on March 5, 2014) and US Application or Patent Cooperation Treaty International Application No. 14/306,382 (filed on June 17, 2014); and filed a patent for using mTORC1 inhibitors to augment the effects of antidepressants (filed on August 20, 2018). All other co-authors declare no competing interests.

ACKNOWLEDGEMENTS

The authors would like to thank the subjects who participated in these studies for their invaluable contribution. Data used in the preparation of this paper were obtained and analyzed from the controlled access data sets distributed from the NIMH-supported National Database for Clinical Trials (NDCT). NDCT is a collaborative informatics system created by the National Institute of Mental Health to provide a national resource to support and accelerate discovery related to clinical trial research in mental health. Data set identifier(s): STU 092010-151; Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC). This paper reflects the views of the authors and may not reflect the opinions or views of the NIMH or of the individuals submitting original data to the NDCT.

AUTHOR CONTRIBUTIONS

Conceptualization: CGA, JHK, and NRD; methodology: CGA; data curation: KHA, SN, MR, PTM, DCD, DHM, and NRD; formal analysis: CGA; investigation: CGA, KHA, LAA, SN, CLA, SF, MR, PTM, DCD, DHM, JHK, and NRD; writing—original draft: CGA, JHK, and NRD; writing—review/edit: all authors; funding acquisition: CGA, DHM, JHK, and NRD; resources: CGA, LAA, and NRD; supervision: CGA, JHK, and NRD.

ADDITIONAL INFORMATION

Supplementary information accompanies this paper at (<https://doi.org/10.1038/s41386-020-00864-9>).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES

1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. *Biol Psychiatry*. 2000;47:351–4.
2. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. *Am J Psychiatry*. 2013;170:1134–42.
3. Zarate CA Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Arch Gen Psychiatry*. 2006;63:856–64.
4. Kraus C, Wasserman D, Henter ID, Acevedo-Diaz E, Kadriu B, Zarate CA, Jr. The influence of ketamine on drug discovery in depression. *Drug Discov Today*. 2019. <https://doi.org/10.1016/j.drudis.2019.07.007>.
5. Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. *Biol Psychiatry*. 2013;73:1133–41.
6. Finn ES, Shen X, Scheinost D, Rosenberg MD, Huang J, Chun MM, et al. Functional connectome fingerprinting: identifying individuals using patterns of brain connectivity. *Nat Neurosci*. 2015;18:1664–71.
7. Nemati S, Abdallah CG. Increased cortical thickness in patients with major depressive disorder following antidepressant treatment. *Chronic Stress*. 2020;4:247054701989996.
8. Akiki TJ, Averill CL, Wrocklage KM, Scott JC, Averill LA, Schweinsburg B, et al. Default mode network abnormalities in posttraumatic stress disorder: a novel network-restricted topology approach. *NeuroImage* 2018;176:489–98.
9. Shen X, Finn ES, Scheinost D, Rosenberg MD, Chun MM, Papademetris X, et al. Using connectome-based predictive modeling to predict individual behavior from brain connectivity. *Nat Protoc*. 2017;12:506–18.
10. Akiki TJ, Abdallah CG. Determining the hierarchical architecture of the human brain using subject-level clustering of functional networks. *Sci Rep*. 2019;9:19290.
11. Nemati S, Akiki TJ, Roscoe J, Ju Y, Averill CL, Fouda S, et al. A unique brain connectome fingerprint predates and predicts response to antidepressants. *iScience*. 2020;23:100800.
12. Abi-Dargham A, Horga G. The search for imaging biomarkers in psychiatric disorders. *Nat Med*. 2016;22:1248–55.
13. Abdallah CG, Averill CL, Salas R, Averill LA, Baldwin PR, Krystal JH, et al. Prefrontal connectivity and glutamate transmission: relevance to depression pathophysiology and ketamine treatment. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2017;2:566–74.
14. D'Souza DC, Carson RE, Driesen N, Johannesen J, Ranganathan M, Krystal JH, et al. Dose-related target occupancy and effects on circuitry, behavior, and neuroplasticity of the glycine transporter-1 inhibitor PF-03463275 in healthy and schizophrenia subjects. *Biol Psychiatry*. 2018;84:413–21.
15. Driesen NR, McCarthy G, Bhagwagar Z, Bloch MH, Calhoun VD, D'Souza DC, et al. The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity. *Neuropsychopharmacology*. 2013;38:2613–22.
16. Trivedi MH, McGrath PJ, Fava M, Parsey RV, Kurian BT, Phillips ML, et al. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): rationale and design. *J Psychiatr Res*. 2016;78:11–23.
17. Javitt DC, Carter CS, Krystal JH, Kantrowitz JT, Girgis RR, Kegeles LS, et al. Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders: a randomized clinical trial. *JAMA Psychiatry*. 2018;75:11–9.
18. Greenberg T, Chase HW, Almeida JR, Stiffler R, Zevallos CR, Aslam HA, et al. Moderation of the relationship between reward expectancy and prediction error-related ventral striatal reactivity by anhedonia in unmedicated major depressive disorder: findings from the EMBARC study. *Am J Psychiatry*. 2015;172:881–91.
19. Glasser MF, Sotiropoulos SN, Wilson JA, Coalson TS, Fischl B, Andersson JL, et al. The minimal preprocessing pipelines for the Human Connectome Project. *NeuroImage*. 2013;80:105–24.
20. Abdallah CG, Averill CL, Ramage AE, Averill LA, Alkin E, Nemati S, et al. Reduced salience and enhanced central executive connectivity following PTSD treatment. *Chronic Stress*. 2019;3:2470547019838971.
21. Abdallah CG, Averill CL, Ramage AE, Averill LA, Goktas S, Nemati S, et al. Salience network disruption in U.S. Army Soldiers with posttraumatic stress disorder. *Chronic Stress*. 2019;3:2470547019850467.
22. Abdallah CG, Dutta A, Averill CL, McKie S, Akiki TJ, Averill LA, et al. Ketamine, but Not the NMDAR antagonist lanicemine, increases prefrontal global connectivity in depressed patients. *Chronic Stress*. 2018;2:2470547018796102.

23. Salimi-Khorshidi G, Douaud G, Beckmann CF, Glasser MF, Griffanti L, Smith SM. Automatic denoising of functional MRI data: combining independent component analysis and hierarchical fusion of classifiers. *NeuroImage*. 2014;90:449–68.
24. Griffanti L, Salimi-Khorshidi G, Beckmann CF, Auerbach EJ, Douaud G, Sexton CE, et al. ICA-based artefact removal and accelerated fMRI acquisition for improved resting state network imaging. *NeuroImage*. 2014;95:232–47.
25. Burgess GC, Kandala S, Nolan D, Laumann TO, Power JD, Adeyemo B, et al. Evaluation of denoising strategies to address motion-correlated artifacts in resting-state functional magnetic resonance imaging data from the Human Connectome Project. *Brain Connect*. 2016;6:669–80.
26. Diedrichsen J, Balsters JH, Flavell J, Cussans E, Ramnani N. A probabilistic MR atlas of the human cerebellum. *NeuroImage*. 2009;46:39–46.
27. Fan L, Li H, Zhuo J, Zhang Y, Wang J, Chen L, et al. The human brainnetome atlas: a new brain atlas based on connectural architecture. *Cereb Cortex*. 2016;26:3508–26.
28. Glasser MF, Coalson TS, Robinson EC, Hacker CD, Harwell J, Yacoub E, et al. A multi-modal parcellation of human cerebral cortex. *Nature*. 2016;536:171–8.
29. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. *Science*. 2012;338:68–72.
30. Abdallah CG, Sanacora G, Duman RS, Krystal JH. The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? *Pharm Ther*. 2018;190:148–58.
31. Abdallah CG, Averill LA, Collins KA, Geha P, Schwartz J, Averill C, et al. Ketamine treatment and global brain connectivity in major depression. *Neuropsychopharmacology*. 2017;42:1210–9.
32. Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, et al. Lower synaptic density is associated with depression severity and network alterations. *Nat Commun*. 2019;10:1529.
33. Kraus C, Mkrchtian A, Kadriu B, Nugent AC, Zarate CA, Jr., Evans JW. Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment. *Neuropsychopharmacology*. 2020. <https://doi.org/10.1038/s41386-020-0624-0>.
34. Murrough JW, Abdallah CG, Anticevic A, Collins KA, Geha P, Averill LA, et al. Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder. *Hum Brain Mapp*. 2016;37:3214–23.
35. Scheinost D, Holmes SE, DellaGioia N, Schleifer C, Matuskey D, Abdallah CG, et al. Multimodal investigation of network level effects using intrinsic functional connectivity, anatomical covariance, and structure-to-function correlations in unmedicated major depressive disorder. *Neuropsychopharmacology*. 2018;43:1119–27.
36. Wang L, Dai Z, Peng H, Tan L, Ding Y, He Z, et al. Overlapping and segregated resting-state functional connectivity in patients with major depressive disorder with and without childhood neglect. *Hum Brain Mapp*. 2014;35:1154–66.
37. Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA. Large-scale network dysfunction in major depressive disorder: a meta-analysis of resting-state functional connectivity. *JAMA Psychiatry*. 2015;72:603–11.
38. Sheline YI, Price JL, Yan Z, Mintun MA. Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. *Proc Natl Acad Sci USA*. 2010;107:11020–5.
39. Yu M, Linn KA, Shinohara RT, Oathes DJ, Cook PA, Duprat R, et al. Childhood trauma history is linked to abnormal brain connectivity in major depression. *Proc Natl Acad Sci USA*. 2019;116:8582–90.
40. Chin Fatt CR, Jha MK, Cooper CM, Fonzo G, South C, Grannemann B, et al. Effect of intrinsic patterns of functional brain connectivity in moderating antidepressant treatment response in major depression. *Am J Psychiatry*. 2020;177:143–54.
41. Driesen NR, McCarthy G, Bhagwagar Z, Bloch M, Calhoun V, D'Souza DC, et al. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. *Mol Psychiatry*. 2013;18:1199–204.
42. Anticevic A, Corlett PR, Cole MW, Savic A, Gancsos M, Tang Y, et al. N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia. *Biol Psychiatry*. 2015;77:569–80.
43. Anticevic A, Gancsos M, Murray JD, Repovs G, Driesen NR, Ennis DJ, et al. NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. *Proc Natl Acad Sci USA*. 2012;109:16720–5.
44. Bonhomme V, Vanhaudenhuyse A, Demertzi A, Bruno MA, Jaquet O, Bahri MA, et al. Resting-state network-specific breakdown of functional connectivity during ketamine alteration of consciousness in volunteers. *Anesthesiology*. 2016;125:873–88.
45. Mueller F, Musso F, London M, de Boer P, Zacharias N, Winterer G. Pharmacological fMRI: effects of subanesthetic ketamine on resting-state functional connectivity in the default mode network, salience network, dorsal attention network and executive control network. *NeuroImage Clin*. 2018;19:745–57.

46. Friston KJ, Buechel C, Fink GR, Morris J, Rolls E, Dolan RJ. Psychophysiological and modulatory interactions in neuroimaging. *NeuroImage*. 1997;6:218–29.
47. Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. *Annu Rev Med*. 2015;66:509–23.
48. McEwen BS. Neurobiological and systemic effects of chronic stress. *Chronic Stress*. 2017;1:1–11.
49. Abdallah CG, Averill LA, Akiki TJ, Raza M, Averill CL, Goma H, et al. The neurobiology and pharmacotherapy of posttraumatic stress disorder. *Annu Rev Pharm Toxicol*. 2019;59:171–89.
50. Abdallah CG, Jackowski A, Salas R, Gupta S, Sato JR, Mao X, et al. The nucleus accumbens and ketamine treatment in major depressive disorder. *Neuropsychopharmacology*. 2017;42:1739–46.
51. Melo A, Kokras N, Dalla C, Ferreira C, Ventura-Silva AP, Sousa N, et al. The positive effect on ketamine as a priming adjuvant in antidepressant treatment. *Transl Psychiatry*. 2015;5:e573.
52. Hare B, Ghosal S, Duman R. Rapid acting antidepressants in chronic stress models: molecular and cellular mechanisms. *Chronic Stress*. 2017;1:1–16.
53. Abdallah CG, De Feyter HM, Averill LA, Jiang L, Averill CL, Chowdhury GMI, et al. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. *Neuropsychopharmacology*. 2018. <https://doi.org/10.1038/s41386-018-0136-3>.
54. Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: progress and prospects. *Nat Rev Drug Discov*. 2017;16:472–86.
55. Liu RJ, Duman C, Kato T, Hare B, Lopresto D, Bang E, et al. GLYX-13 produces rapid antidepressant responses with key synaptic and behavioral effects distinct from ketamine. *Neuropsychopharmacology*. 2017;42:1231–42.
56. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. *Science*. 2010;329:959–64.
57. Abdallah CG, Averill LA, Gueorguieva R, Goktas S, Purohit P, Ranganathan M, et al. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. *Neuropsychopharmacology*. 2020;45:990–7.
58. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. *Nature*. 2011;475:91–5. <https://doi.org/10.1038/nature10130>.